Novel immunotherapy delivery approach safe and beneficial for some melanoma patients with leptomeningeal disease
A novel approach to administer intrathecal (IT) immunotherapy (directly into the spinal fluid) and intravenous (IV) immunotherapy was safe and improved survival in a subset of patients with leptomeningeal disease (LMD) from metastatic melanoma, according to interim analyses of a Phase I/Ib trial led by researchers at Â鶹ӳ» MD?Anderson Cancer Center.
The study, published today in Nature Medicine, represents...
MD Anderson Research Highlights for March 29, 2023
Â鶹ӳ» MD Anderson Cancer Center¡¯s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
Take down tobacco and vape
CORPUS CHRISTI - Over 20 area school districts will come together to "Take down tobacco and vape" at the Corpus Christi Icerays...
Florencia McAllister receives TAMEST Mary Beth Maddox Award for pancreatic tumor microbiome research
Florencia McAllister, M.D., associate professor of Clinical Cancer Prevention, Gastrointestinal Medical Oncology and Immunology at Â鶹ӳ» MD Anderson Cancer Center has been awarded the 2023 Mary Beth Maddox Award and Lectureship in cancer research from the Texas Academy of Medicine, Engineering, Science and Technology (TAMEST).
McAllister is being honored for her pioneering research on the intra-tumoral bacteria...
Dual immunotherapy plus chemotherapy before surgery improves patient outcomes in operable lung cancer
In a Phase II trial led by researchers from Â鶹ӳ» MD Anderson Cancer Center, adding ipilimumab to a neoadjuvant, or pre-surgical...
Kerin Adelson, M.D., named MD Anderson Chief Quality and Value Officer
Â鶹ӳ» MD Anderson Cancer Center today announced Kerin Adelson, M.D., as the institution¡¯s chief quality and value officer...
MD Anderson Research Highlights for March 8, 2023
Â鶹ӳ» MD Anderson Cancer Center¡¯s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...